Información del artículo
Abstract
Anemia is one of the most prevalent diseases in the general population and is a very frequently found condition in medical and surgical patients in all medical specialties. A good evaluation of its clinical impact and its therapeutic possibilities is essential. Allogenic blood transfusion is a useful procedure in anemia management, although it has important adverse effects. It is the responsibility of the clinician to know and to take into account all the available alternatives for the treatment of anemia. Blood transfusions, erythropoiesis-stimulating agents, iron therapy (oral and endovenous) and other therapeutic alternatives must be rationally used, in accordance with the currently available clinical evidence. This review article summarizes some epidemiological characteristics of anemia, its clinical evaluation and the main therapeutic possibilities based on the present knowledge, placing special emphasis on the critically ill patient.
Keywords:
Anemia
Transfusion
Iron Therapy
Resumen
La anemia representa una de las patologías más prevalentes en la población general y constituye una entidad extremadamente frecuente en pacientes médicos y quirúrgicos de todas las especialidades. Una correcta valoración de su impacto y de las posibilidades terapéuticas resulta crucial. La transfusión de sangre alogénica representa una medida eficaz en el manejo de la anemia, pero no está exenta de importantes complicaciones. Es responsabilidad del clínico conocer y sopesar todas las alternativas disponibles para el manejo global de la anemia. Transfusiones sanguíneas, agentes estimuladores de la eritropoyesis, ferroterapia (oral y endovenosa) y otras alternativas terapéuticas han de ser empleadas de forma racional y ajustándonos a la evidencia clínica disponible hasta la fecha. El presente artículo de revisión resume algunas características epidemiológicas de la anemia, su valoración clínica y las principales alternativas terapéuticas a la luz de los conocimientos actuales, con especial énfasis en el paciente crítico.
Palabras clave:
Anemia
Transfusión
Ferroterapia
El Texto completo está disponible en PDF
References
[1.]
H. Gaskell, S. Derry, R.A. Moore, H.J. McQuay.
Prevalence of anaemia in older persons: systematic review.
BMC Geriatrics, 8 (2008), pp. 1-8
[2.]
W. McClellan, S.L. Aronoff, W.K. Bolton, S. Hood, D.L. Lorber, K.L. Tang, et al.
The prevalence of anemia in patients with chronic kidney disease.
Curr Med Res Opin, 20 (2004), pp. 1501-1510
[3.]
N.C. Andrews.
Forging a field: the golden age of iron biology.
Blood, 112 (2008), pp. 219-230
[4.]
P.C. Hébert, G. Wells, M.A. Blajchman, J. Marshall, C. Martin, G. Pagliarello, et al.
A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group.
N Engl J Med, 340 (1999), pp. 409-417
[5.]
S. Fishbane.
Anemia in chronic kidney disease: status of new therapies.
Curr Opin Nephrol Hypertens, 18 (2009), pp. 112-115
[6.]
D.W. Coyne.
A comprehensive vision for intravenous iron therapy.
Am J Kidney Dis, 52 (2008), pp. S14-S20
[7.]
J.E. Novak, L.A. Szczech.
Triumph and tragedy: anemia management in chronic kidney disease.
Curr Opin Nephrol Hypertens, 17 (2008), pp. 580-588
[8.]
J.D. Rizzo, M.R. Somerfield, K.L. Hagerty, J. Seidenfeld, J. Boh- lius, C.L. Bennett, et al.
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update.
J Clin Oncol, 26 (2008), pp. 132-149
[9.]
A.A. Khorana, C.W. Francis, N. Blumberg, E. Culakova, M.A. Refaai, G.H. Lyman.
Blood transfusions, thrombosis, and morta- lity in hospitalized patients with cancer.
Arch Intern Med, 168 (2008), pp. 2377-2381
[10.]
L.B. Harrison, M. Chadha, R.J. Hill, K. Hu, D. Shasha.
Impact of tumor hypoxia and anemia on radiation therapy outcomes.
Oncologist, 7 (2002), pp. 492-508
[11.]
J.U. Blohmer, J. Dunst, L. Harrison, P. Johnston, D. Khayat, H. Ludwig, et al.
Cancer-related anemia: biological findings, clinical implications and impact on quality of life.
Oncology, 68 (2005), pp. S12-S21
[12.]
J.L. Vincent, J.F. Baron, K. Reinhart, L. Gattinoni, L. Thijs, A. Webb, et al.
Anemia and blood transfusion in critically ill patients.
JAMA, 288 (2002), pp. 1499-1507
[13.]
H.L. Corwin, A.F. Shorr.
Red blood cell transfusion in the critically ill: when is it time to say enough?.
Crit care Med, 37 (2009), pp. 2114-2116
[14.]
H.L. Corwin, A. Gettinger, T.C. Fabian, A. May, R.G. Pearl, S. Heard, et al.
Efficacy and safety of epoetin alfa in critically ill patients.
N Engl J Med, 357 (2007), pp. 965-976
[15.]
P.E. Marik, H.L. Corwin.
Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature.
Crit Care Med, 36 (2008), pp. 1-8
[16.]
M. Muñoz, S.R. Leal-Noval, J.A. García-Erce, E. Naveira.
Prevalencia y tratamiento de la anemia en el paciente crítico.
Med Intensiva, 31 (2007), pp. 388-398
[17.]
I. Alberca, M.S. Asuero, J.L. Bóveda, N. Carpio, E. Contreras, E. Fernández Mondéjar, et al.
Documento “Sevilla” de consenso sobre alternativas a la transfusión de sangre alogénica.
Med Clin (Barc), 127 (2006), pp. S3-S20
[18.]
K.W. Park, D. Chandhok.
Transfusion-associated complications.
Int Anesthesiol Clin, 42 (2004), pp. 11-26
[19.]
L.T. Goodnough.
Risks of blood transfusion.
Crit Care Med, 31 (2003), pp. S678-S686
[20.]
S.R. Leal-Noval, M. Muñoz, A. Campanario.
Transfusión en el paciente crítico.
Med Intensiva, 28 (2004), pp. 464-469
[21.]
G. Liumbruno, F. Bennardello, A. Lattanzio, P. Piccoli, G. Rossetti.
Recommendations for the transfusion of red blood cells.
Blood Transfus, 7 (2009), pp. 49-64
[22.]
C. Madjdpour, D.R. Spahn, R.B. Weiskopf.
Anemia and perioperative red blood cell transfusion: a matter of tolerance.
Crit Care Med, 34 (2006), pp. S102-S108
[23.]
A. Pape, P. Stein, O. Horn, O. Habler.
Clinical evidence of blood transfusion effectiveness.
Blood Transfus, 7 (2009), pp. 250-258
[24.]
A.T. Tinmouth, L.A. McIntyre, R.A. Fowler.
Blood conservation strategies to reduce the need for red blood cell transfusion in critically ill patients.
CMAJ, 178 (2008), pp. 49-57
[25.]
P.J. Ratcliffe.
HIF-1 and HIF-2: working alone or together in hypoxia?.
J Clin Invest, 117 (2007), pp. 862-865
[26.]
J. Gramm, S. Smith, R.L. Gamelli, D.J. Dries.
Effect of transfusion on oxygen transport in critically ill patients.
Shock, 5 (1996), pp. 190-193
[27.]
L.M. Napolitano, S. Kurek, F.A. Luchette, G.L. Anderson, M.R. Bard, W. Bromberg, et al.
Clinical practice guideline: red blood cell transfusion in adult trauma and critical care.
J Trauma, 67 (2009), pp. 1439-1442
[28.]
M. Quintana, M. Sánchez, S.R. Leal-Noval, A. García.
Resultados de una encuesta nacional sobre hábito transfusional en unidades de cuidades intensivos.
Med Intensiva, 33 (2009), pp. 8-15
[29.]
P.C. Hébert, A. Tinmouth, H.L. Corwin.
Controversies in RBC transfusion in the critically ill.
Chest, 131 (2007), pp. 1583-1590
[30.]
J.A. García-Erce, F. Gomollón, M. Muñoz.
Blood transfusion for the treatment of acute anaemia in inflammatory bowel disease and other digestive diseases.
World J Gastroenterol, 15 (2009), pp. 4686-4694
[31.]
H.L. Corwin, A. Gettinger, R.G. Pearl, M.P. Fink, M.M. Levy, E. Abraham, et al.
The CRIT study: anemia and blood transfusion in the critically ill-Current clinical practice in the United States.
Crit Care Med, 32 (2004), pp. 39-52
[32.]
S.R. Leal-Noval, M.D. Rincón-Ferrari, A. Marin-Niebla, A. Cayuela, V. Arellano-Orden, A. Marín-Caballos, et al.
Transfusion of erythrocyte concentrates produces a variable increment on cerebral oxygenation in patients with severe traumatic brain injury: a preliminary study.
Intensive Care Med, 32 (2006), pp. 1733-1740
[33.]
D.A. Zygun, J. Nortje, P.J. Hutchinson, I. Timofeev, D.K. Menon, A.K. Gupta.
The effect of red blood cell transfusion on cere- bral oxygenation and metabolism after severe traumatic brain injury.
Crit Care Med, 37 (2009), pp. 1074-1078
[34.]
M. Muñoz, A. Romero, M. Morales, A. Campos, J.A. García-Erce, G. Ramírez.
Iron metabolism, inflammation and anemia in critically ill patients. A cross-sectional study.
Nutr Hosp, XX (2005), pp. 115-120
[35.]
R. Zarychanski, A.F. Turgeon, L. McIntyre, D.A. Fergusson.
Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials.
CMAJ, 177 (2007), pp. 725-734
[36.]
B.S. Skikne.
Serum transferring receptor.
Am J Hematol, 83 (2008), pp. 872-875
[37.]
G. Weiss, L.T. Goodnough.
Anemia of chronic disease.
N Engl J Med, 352 (2005), pp. 1011-1023
[38.]
M.C. Bellamy, J.A. Gednaey.
Unrecognised iron deficiency in critical illness.
Lancet, 352 (1998), pp. 1903
[39.]
A.C. Bernard, D.L. Davenport, P.K. Chang, T.B. Vaughan, J.B. Zwischenberger.
Intraoperative transfusion of 1 U to 2 U packed red blood cells is associated with increased 30-day mortality, surgical-site infection, pneumonia, and sepsis in general surgery patients.
J Am Coll Surg, 208 (2009), pp. 931-937
[40.]
J. Sadjadi, E.L. Cureton, P. Twomey, G.P. Victorino.
Transfusion, not just injury severity, leads to posttrauma infection: a matched cohort study.
Am Surg, 75 (2009), pp. 307-312
[41.]
J.E. Hendrickson, C.D. Hillyer.
Noninfectious serious hazards of transfusion.
Anesth Analg, 108 (2009), pp. 759-769
[42.]
J.L. Vincent, Y. Sakr, C. Sprung, S. Harboe, P. Damas.
Are blood transfusions associated with greater mortality rates?.
Anesthesiology, 108 (2008), pp. 31-39
[43.]
E.C. Vamvakas, M.A. Blajchman.
Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the availa- ble strategies for their prevention.
Blood, 113 (2009), pp. 3406-3417
[44.]
M.K. Hourfar, C. Jork, V. Schottstedt, M. Weber-Schehl, V. Brixner, M.P. Busch.
Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.
Transfusion, 48 (2008), pp. 1558-1566
[45.]
M.A. Blajchman, E.C. Vamvakas.
The continuing risk of transfusiontransmitted infections.
N Engl J Med, 355 (2006), pp. 1303-1305
[46.]
Taylor C, Cohen H, Mold D, Jones H, Asher D, Cawley C, et al. On behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2008 Annual SHOT Report (2009).
[47.]
E.A. Katz.
Blood transfusion: friend or foe.
AACN Adv Crit Care, 20 (2009), pp. 155-163
[48.]
P.E. Marik, H.L. Corwin.
Acute lung injury following blood transfusion: expanding the definition.
Crit Care Med, 36 (2008), pp. 3080-3084
[49.]
M.M. Lange, J.A. van Hilten, L.M. Van de Watering, B.A. Bijnen, R.M. Roumen, H. Putter, et al.
Leucocyte depletion of perioperative blood transfusion does not affect long-term survival and recurrence in patients with gastrointestinal cancer.
Br J Surg, 96 (2009), pp. 734-740
[50.]
C.G. Koch, L. Li, D.I. Sessler, P. Figueroa, G.A. Hoeltge, T. Mihaljevic, et al.
Duration of red-cell storage and complications after cardiac surgery.
N Engl J Med, 358 (2008), pp. 1229-1239
[51.]
H.J. Nielsen, C.M. Reimert, A.N. Pedersen, N. Brünner, L. Edvardsen, E. Dybkjaer, et al.
Time-dependent, spontaneous release of white cell- and platelet-derived bioactive substances from stored human blood.
Transfusion, 36 (1996), pp. 960-965
[52.]
C. Bokemeyer, M.S. Aapro, A. Courdi, J. Foubert, H. Link, A. Osterborg, et al.
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.
Eur J Cancer, 43 (2007), pp. 258-270
[53.]
B. Michaeli, P. Ravussin, P.G. Chassot.
Autologous blood predonation and perioperative use of erythropoietin.
Rev Med Suisse, 2 (2006), pp. 2662-2664
[54.]
L. Del Vecchio, F. Locatelli.
New erythropoiesis-stimulating agents: how innovative are they?.
Contrib Nephrol, 161 (2008), pp. 255-260
[55.]
J. Rossert, K.U. Eckardt.
Erythropoietin receptors: their role beyond erythropoiesis.
Nephrology Dialysis Transplantation, 20 (2005), pp. 1025-1028
[56.]
C. Gasché, C. Dejaco, T. Waldhoer, W. Tillinger, W. Reinisch, G.F. Fueger, et al.
Intravenous iron and erythropoietin for ane- mia associated with Crohn disease. A randomized, controlled trial.
Ann Intern Med, 126 (1997), pp. 782-787
[57.]
Epoetinas: nuevas recomendaciones de uso (ref:2008/10,junio).
Inf Ter Sist Nac Salud, 32 (2008), pp. 95-96
[58.]
J. Bohlius, K. Schmidlin, C. Brillant, G. Schwarzer, S. Trelle, J. Seidenfeld, et al.
Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.
Lancet, 373 (2009), pp. 1532-1542
[59.]
H.L. Corwin, A. Gettinger, R.G. Pearl, M.P. Fink, M.M. Levy, M.J. Shapiro, et al.
Efficacy of recombinant human erythropoietin in critically ill patients: a randomized, controlled trial.
JAMA, 288 (2002), pp. 2827-2835
[60.]
M. Silver, M.J. Corwin, A. Bazan, A. Gettinger, C. Enny, H.L. Corwin.
Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
Crit Care Med, 34 (2006), pp. 2310-2316
[61.]
G. Bodemar, S. Kechagias, S. Almer, B.G. Danielson.
Treatment of anemia in inflammatory bowel disease with iron sucrose.
Scand J Gastroenterol, 39 (2004), pp. 454-458
[62.]
S. Kulnigg, S. Stoinov, V. Simanenkov, L.V. Dudar, KarnafelW, L.C. Garcia, et al.
A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The Ferric Carboxymaltose (FERINJECT®) Randomized Controlled Trial.
Am J Gastroenterol, 103 (2008), pp. 1182-1192
[63.]
B. Rozen-Zvi, A. Gafter-Gvili, M. Paul, L. Leibovici, O. Shpilberg, U. Gafter.
Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and metaanalysis.
Am J Kidney Dis, 52 (2008), pp. 897-906
[64.]
C.E. Van Iperen, C.A. Gaillard, R.J. Kraaijenhagen, B.G. Braam, J.J. Marx, A. van de Wiel.
Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients.
Crit Care Med, 28 (2000), pp. 2773-2778
[65.]
D. Georgopoulos, D. Matamos, C. Routsi, A. Michalopoulos, N. Margina, G. Dimopoulos, et al.
Recombinant human erythropoietin therapy in critically ill patients: a dose-response study.
Crit Care, 9 (2005), pp. R508-R515
[66.]
A.M. Mahdy, N.R. Webster.
Perioperative systemic haemostatic agents.
Br J Anaesth, 93 (2004), pp. 842-858
[67.]
D.A. Fergusson, P.C. Hébert, C.D. Mazer, S. Fremes, C. MacA- dams, J.M. Murkin, et al.
A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.
N Engl J Med, 358 (2008), pp. 2319-2331
[68.]
D. Oertli, U. Laffer, F. Haberthuer, U. Kreuter, F. Harder.
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Br J Surg, 81 (1994), pp. 856-859
[69.]
C. Natanson, S.J. Kern, P. Lurie, S.M. Banks, S.M. Wolfe.
Cell-free haemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis.
JAMA, 299 (2008), pp. 2304-2312
Copyright © 2011. Elsevier y Sociedad Española de Medicina Intensiva, Critica y Unidades Coronarias
